Spedding M, Newman-Tancredi A, Millan M J, Dacquet C, Michel A N, Jacoby E, Vickery B, Tallentire D
Institut de Internationales, Servier, Croissy Research Centre, Paris, France.
Neuropharmacology. 1998 Jun;37(6):769-80. doi: 10.1016/s0028-3908(98)00065-3.
RS-30199 has been shown previously to have atypical interactions at 5-HT1A receptors. RS-30199 and RS-64459, an analogue of buspirone with a buspirone side chain, were compared with the classic, partial agonist at 5-HT1A receptors, 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) and buspirone. At human (h) 5-HT1A receptors in CHO cells, RS-30199-193 (racemate) and its enantiomers (-197, -198) inhibited [3H]-8-OH-DPAT binding (RS-30199-198, ki, 29.7 +/- 11.7 nM; RS-30199-197, ki, 74.1 +/- 11.7 nM) as did RS-64459 (ki, 24.9 +/- 6.0 nM), but RS-30199-197 and -198 were almost full agonists in a [35S]-GTPgammaS binding assay, whereas RS-64459 was a partial agonist, resembling buspirone and 8-OH-DPAT. RS-64459 and the enantiomers of RS-30199 had weaker affinity for 5-HT2C and 5-HT7 receptors. These compounds did not induce the 5-HT behavioural syndrome in male rats. However, in a model where naive male rats were introduced to estrogen-progesterone primed, sexually receptive female rats, RS-30199-197 (0.1, 1, 10 mg/kg, s.c.) had a profound inhibitory effect on sexual behaviour score. Neither buspirone nor 8-OH-DPAT reduced the sexual behaviour score. Unlike 8-OH-DPAT, which shortens intromission latency, RS-30199 prolonged intromission latency. RS-30199 (10 mg/kg s.c.) fully inhibited the facilitation of sexual behaviour caused by the alpha2-adrenoceptor antagonist, delequamine (0.1 mg/kg, p.o.). In contrast, RS-64459 (100, 250, 1000 and 4000 microg/kg, s.c.) failed to modify the sexual behaviour score and did not modify intromission latency. The differences between the effects of RS-30199 and RS-64459 in binding and functional experiments are supported by molecular models of the receptor-ligand interaction, where the compounds interact in different ways with the receptor; a model is proposed for the allosteric interaction of different agents with the receptor, resulting in different functional profiles. RS-30199 can be considered an atypical agonist at 5-HT1A receptors.
先前已证明RS - 30199在5 - HT1A受体上具有非典型相互作用。将RS - 30199和RS - 64459(一种具有丁螺环酮侧链的丁螺环酮类似物)与经典的5 - HT1A受体部分激动剂8 - 羟基 - 2(二正丙基氨基)四氢萘(8 - OH - DPAT)和丁螺环酮进行比较。在CHO细胞中的人(h)5 - HT1A受体上,RS - 30199 - 193(外消旋体)及其对映体(-197,-198)抑制[3H] - 8 - OH - DPAT结合(RS - 30199 - 198,抑制常数ki为29.7±11.7 nM;RS - 30199 - 197,ki为74.1±11.7 nM),RS - 64459(ki为24.9±6.0 nM)也是如此,但在[35S] - GTPγS结合试验中,RS - 30199 - 197和-198几乎是完全激动剂,而RS - 64459是部分激动剂,类似于丁螺环酮和8 - OH - DPAT。RS - 64459和RS - 30199的对映体对5 - HT2C和5 - HT7受体的亲和力较弱。这些化合物在雄性大鼠中未诱发5 - HT行为综合征。然而,在一个将未接触过异性的雄性大鼠引入经雌激素 - 孕酮预处理且具有性接受能力的雌性大鼠的模型中,RS - 30199 - 197(0.1、1、10 mg/kg,皮下注射)对性行为评分有显著抑制作用。丁螺环酮和8 - OH - DPAT均未降低性行为评分。与缩短插入潜伏期的8 - OH - DPAT不同,RS - 30199延长了插入潜伏期。RS - 30199(10 mg/kg皮下注射)完全抑制了α2 - 肾上腺素能受体拮抗剂地来夸明(0.1 mg/kg,口服)对性行为的促进作用。相比之下,RS - 64459(100、250、1000和4000 μg/kg,皮下注射)未能改变性行为评分,也未改变插入潜伏期。受体 - 配体相互作用的分子模型支持了RS - 30199和RS - 64459在结合和功能实验中效应的差异,其中这些化合物与受体以不同方式相互作用;提出了一个不同药物与受体变构相互作用的模型,导致不同的功能特征。RS - 30199可被认为是5 - HT1A受体的非典型激动剂。